...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >Pixantrone maleate for non-Hodgkin's lymphoma.
【24h】

Pixantrone maleate for non-Hodgkin's lymphoma.

机译：Pixantrone Maleate用于非霍奇金的淋巴瘤。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Pixantrone (BBR-2778) is a novel aza-anthracenedione anthracycline derivative developed by Cell Therapeutics Incorporated, WA, USA. Pixantrone is similar in structure to the anthracenedione mitoxantrone but lacks the 5, 8-dihydroxy substitution groups implicated in mitoxantrone-induced cardiotoxicity. The PIX301 phase III single-agent trial of pixantrone for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma randomized patients to receive either pixantrone or another single agent of the investigators' choice. The rate of confirmed and unconfirmed remissions in patients treated with pixantrone was significantly higher than in those receiving other agents, as was the overall response rate and progression-free survival. There is evidence that pixantrone is well tolerated when substituted for anthracyclines in combination regimens for aggressive non-Hodgkin's lymphoma with comparable rates of complete remission. Pixantrone has also been used for the treatment of indolent non-Hodgkin's lymphomas and the combination of pixantrone and rituximab has been shown to be superior to rituximab alone in relapsed or refractory disease in the phase III PIX302 study. On the basis of these data, the United States Food and Drug Administration is considering pixantrone for use in adult patients with relapsed or refractory aggressive and indolent non-Hodgkin's lymphoma on a fast-track basis.
机译：Pixantrone（BBR-2778）是由美国的细胞治疗剂开发的新型Aza-anthacentione蒽丙氨酸衍生物。 PIXANTRONE在结构上与蒽酮丝氧化酮的结构相似，但缺乏含有丝洛酮类诱导的心脏毒性的5,8-二羟基取代基团。 PIX301期III单孕二酮试验PIXPANTONE对复发或难治性侵袭性非霍奇金淋巴瘤随机化患者接受PIXANTRONE或其他调查人员选择的另一个药剂。用Pixantrone治疗的患者的确诊和未经证实的剩余率明显高于接受其他药剂的患者，以及整体反应率和无进展的存活率。有证据表明，当炭疽霉素中的蒽环类药物中的蒽环类药物的淋巴瘤的组合方案具有相当的完全缓解率时，PIXTANTRONE具有良好的耐受性。 Pixantrone还被用于治疗惰性非霍奇金淋巴瘤的淋巴瘤，并且PIXONTRONE和RITUXIMAB的组合已被证明是在III PIX302研究中的复发或难治性疾病中优于Rituximab。在这些数据的基础上，美国食品和药物管理局正在考虑Pixantrone用于成年患者，以快速轨道的基础上复发或难以丧失的侵袭性和惰性非霍奇金淋巴瘤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号